The University of California Center for Accelerated Innovation proposes to create new mechanisms and to leverage its diverse strengths in diagnostics, therapeutics, and devices to support translation of promising early-stage inventions for patient benefit. The Center is a consortium of the five UC medical campuses: UC Davis, UC Irvine, UC Los Angeles, UC San Diego, and UC San Francisco. Each campus has a thriving research enterprise, nationally ranked medical school, and translational research institute funded by Clinical and Translational Science Awards (CTSA). Together, our five campuses account for nearly 7% of NHLBI's grant funding. The Center taps into the vigor and creativity of California's legendary biomedical and engineering ecosystem and integrates the many successful business, engineering and health sciences programs at our campuses. Our program will partner with well-established biomedical companies, venture capital firms, industry organizations and nonprofits focused on medical innovation. The Center is supported by UC Biomedical Research Acceleration, Integration, and Development (UC BRAID), a joint effort of the five UC biomedical campuses designed to catalyze and accelerate biomedical, clinical, and translational research across the UC system. Together we will: 1) Engage University of California heart, lung and blood disease innovators in entrepreneurism through a comprehensive education, training and mentorship program. 2) Solicit and select technologies with high commercial potential that align with NHLBI's mission and address unmet medical needs or significant scientific opportunity. 3) Incubate our most promising technologies in accordance with industry requirements to facilitate their translation to commercial products that improve patient care and enhance health. 4) Create a high-performing, sustainable infrastructure that will serve as a model to academic research centers. These programs will create an integrated, sustainable infrastructure to accelerate the translation of our NHLBI-funded discoveries to the marketplace in order to promote health and improve patient care.
The University of California Center for Accelerated Innovation, a consortium of the five UC medical campuses: UC Davis, UC Irvine, UC Los Angeles, UC San Diego, and UC San Francisco, proposes a comprehensive program to transform new biomedical inventions by faculty and staff into highly effective medications, diagnostic tests and medical devices.
|Cormier, Anthony; Campbell, Melody G; Ito, Saburo et al. (2018) Cryo-EM structure of the ?v?8 integrin reveals a mechanism for stabilizing integrin extension. Nat Struct Mol Biol 25:698-704|
|Takasaka, Naoki; Seed, Robert I; Cormier, Anthony et al. (2018) Integrin ?v?8-expressing tumor cells evade host immunity by regulating TGF-? activation in immune cells. JCI Insight 3:|
|Fong, Valerie; Hsu, Austin; Wu, Esther et al. (2018) Arhgef12 drives IL17A-induced airway contractility and airway hyperresponsiveness in mice. JCI Insight 3:|
|Cranford, Jonathan P; O'Hara, Thomas J; Villongco, Christopher T et al. (2018) Efficient Computational Modeling of Human Ventricular Activation and Its Electrocardiographic Representation: A Sensitivity Study. Cardiovasc Eng Technol 9:447-467|
|Hanudel, Mark R; Rappaport, Maxime; Chua, Kristine et al. (2018) Levels of the erythropoietin-responsive hormone erythroferrone in mice and humans with chronic kidney disease. Haematologica 103:e141-e142|
|Hou, Andrew J; Chang, ZeNan L; Lorenzini, Michael H et al. (2018) TGF-?-responsive CAR-T cells promote anti-tumor immune function. Bioeng Transl Med 3:75-86|
|Fidler, Richard L; Pelter, Michele M; Drew, Barbara J et al. (2017) Understanding heart rate alarm adjustment in the intensive care units through an analytical approach. PLoS One 12:e0187855|
|Ivry, Sam L; Sharib, Jeremy M; Dominguez, Dana A et al. (2017) Global Protease Activity Profiling Provides Differential Diagnosis of Pancreatic Cysts. Clin Cancer Res 23:4865-4874|
|Antman, Elliott M; Di Corleto, Paul E; Freeman, Mason W et al. (2017) NIH Centers for Accelerated Innovations Program: principles, practices, successes and challenges. Nat Rev Drug Discov 16:663-664|
|Ganz, Tomas; Jung, Grace; Naeim, Arash et al. (2017) Immunoassay for human serum erythroferrone. Blood 130:1243-1246|
Showing the most recent 10 out of 15 publications